Illustration: Inc.; Photo: Getty Images; Courtesy company

Hey everyone, welcome back to Inc.’s 1 Smart Business Story! For years, peptides lived on the fringes of wellness culture, embraced by biohackers, elite athletes, and longevity obsessives. Now a new crop of startups is betting that entrepreneurs and executives are the next big market.

Serial founder Tony Medrano says peptide therapies have helped him dramatically improve his health, athletic performance, and career performance. His company, LongevityPlan.AI, is a startup that uses bloodwork, wearable-device data, and AI-generated health recommendations to guide other high achievers on their peptide journey as they optimize everything from energy and recovery to weight management and sleep.

However, most peptides remain in a regulatory gray zone, Inc. senior writer Sam Blum reports. While an FDA advisory panel recently recommended several peptides for potential compounding approval, the drugs are not yet fully authorized, and many are still sold as "research-use-only" products. But that has not stopped VC-backed peptide platforms and other founders from rushing in on what they see as a potential goldmine.

These startups are increasingly pitching peptides as productivity tools for executives seeking an edge in performance, focus, recovery, and longevity. In other words, it’s the biotech version of the hustle culture playbook.

In this story you’ll discover:

  • That building a brand before regulation rules are set can be a big risk—but also have a big payoff

  • How a founder pivoted a niche health product to a new audience: executives and business leaders

  • Why AI is becoming the sales engine for health analytics brands

Like what you’re reading? Subscribe to Inc. for just $1 for your first month to find out everything you need to know to start and grow your business.

The Peptide Boom Is Coming for the C-Suite

A growing industry of telehealth startups and coaches is marketing peptides to entrepreneurs and execs, even as most of the drugs remain unapproved and stuck in a regulatory gray zone.

BY SAM BLUM, SENIOR WRITER

Tony Medrano says peptides are helping him age in reverse. There are many influencers, celebrities, and VC-backed startups singing the praises of peptides, but Medrano, a serial tech founder, might be one of the most compelling examples in the growing wave of evangelists. That’s because Medrano, a 55-year-old Stanford Business School graduate and lawyer, isn’t really 55—or so he claims.

Medrano says his “metabolic age” is 41 and his “biological age” is 28. (For Medrano, who was born in 1971, 55 is merely his “chronological age.”) He credits injecting peptides—small chains of amino acids that regulate a variety of hormonal processes such as muscle growth, energy, sleep, and weight loss—with his ability to compete in Ironman triathlons and train four hours a day, five days a week.

Medrano believes legions of other people, specifically entrepreneurs and workers looking to optimize their mental and physical health, will adopt peptide injections in an effort to climb the corporate ladder. In 2025, he founded LongevityPlan.AI to advise and assist customers in this pursuit. He hopes to eventually bring the drugs to corporate health care packages as a benefit, similar to a gym membership option, he says.

Unlike many longevity enthusiasts, who adopt protocols at great financial expense, LongevityPlan.AI’s clients can obtain peptide consulting at a modest monthly fee. For $39 a month, the San Diego-based company gives customers an AI-generated “digital twin,” built from bloodwork and wearable data, which they can pair with peptides sourced on their own. To acquire peptides, customers can also go through LongevityPlan.AI’s physician-prescribed track: an intake form, review fee, and a prescription shipped to their door, along with a complimentary wearable that feeds data to the digital twin over 90 days. 

Alternatively, customers can browse and buy the drugs directly from the site. Non-FDA-certified peptides carry a disclaimer stating the products are sold for research purposes only, not intended for human consumption or therapeutic treatment, and that buyers must be over 21 and understand the research-use-only nature of the product. Medrano says they are for taking “at your own risk.” 

“I have used all of those peptides myself because I only believe in promoting things that I would do myself and that have helped me,” Medrano says, claiming that BPC-157, a non-FDA-approved peptide available on LongevityPlan.AI, commonly used to recover from physical strain on the body, fixed a 30-year-old knee injury of his in two weeks. 

Medrano says he welcomes the skeptics and critics of the peptide industry: “Breakthroughs always breed naysayers and people who are afraid of change.”

Regulatory lanes open up for peptides

In July, PCAC—a group of independent experts assembled by the FDA to provide guidance on pharmaceutical compounding—voted to recommend six peptides for the FDA’s 503A Bulks List. That’s the classification deemed safe for production at U.S. compounding pharmacies, which make custom prescription drugs from raw ingredients. 

Many media reports framed the recommendation as a watershed moment that could spur the mainstream emergence of peptides. The reality, however, is that most of these drugs still operate in a regulatory gray area. The advisory group’s vote is more like nudging the ball down the field than marching it into the end zone: The FDA’s scientists still have to deliberate on whether to recommend the peptides for compounding until after a public comment period—a process that won’t be finalized until 2027 at the earliest. 

“The PCAC panel vote actually didn’t change anything,” says Haleem Mohammed, a PCAC member and the global chief medical officer at Gameday Health. These six peptides still sit in “advisory-recommended, not yet authorized” status, and are sold as “research-only” compounds while the 503A rulemaking is pending. But the vote does signal a growing acceptance of peptides generally, as well as a belief among founders that if and when regulatory lanes open up, they will be ideally positioned to cash in. 

Medrano isn’t the only founder betting on the space between “recommended” and “authorized.” VC-backed Feel Peptides has $3 million from Sugar Capital behind it, and NoHo Labs has $16 million from Elad Gil and Joe Lonsdale’s 8VC, and both are poised to benefit while the regulatory vacuum lasts, before the rulemaking catches up (though NoHo Labs recently removed gray-market drugs from its site).

While Feel Peptides uses vague lifestyle identifiers like “Love” and “Youth” to imbue different drug combinations with a kind of gentle branding, Medrano’s scrappier operation leans into tech-heavy methods, courtesy of its digital twin. Operating in a gray-market regulatory space is riskier for an entrepreneur like Medrano, who lacks the millions in VC capital that larger players have. But the potential return on that risk could be considerable if things play out in his favor.

5 More Smart Business Stories:

Turn AI into Your Income Engine

Ready to transform artificial intelligence from a buzzword into your personal revenue generator

HubSpot’s groundbreaking guide "200+ AI-Powered Income Ideas" is your gateway to financial innovation in the digital age.

Inside you'll discover:

  • A curated collection of 200+ profitable opportunities spanning content creation, e-commerce, gaming, and emerging digital markets—each vetted for real-world potential

  • Step-by-step implementation guides designed for beginners, making AI accessible regardless of your technical background

  • Cutting-edge strategies aligned with current market trends, ensuring your ventures stay ahead of the curve

Download your guide today and unlock a future where artificial intelligence powers your success. Your next income stream is waiting.